Karamvir Yadav, Medical Oncologist in Jaipur, India, shared a post on X:
“Relapsed GCT: Who truly benefits from HDCT?
Baseline plasma tumor fraction stratifies risk. High TF identifies poor prognosis – but also those who may derive greater benefit from HDCT vs CDCT.
CNA clustering reveals an aggressive extra-embryonic genomic subtype.
Precision salvage therapy is coming.”
Other articles featuring Karamvir Yadav on OncoDaily.